A niche player $IRMD (-1,34Â %) in the healthcare sector; strong quarter, but management has slightly lowered its guidance. If the stock price drops a bit more, the valuation could become attractive again...
2Sem.·
Iradimed Q3/26 Earnings
33
2 CommentairesBrian@Aktienhauptmeister
2Sem.
•
22
•Stocktective@Stocktective
2Sem.
••